Marinus Pharmaceuticals, Inc. (MRNS)
Feb 11, 2025 - MRNS was delisted (reason: acquired by Immedica)
0.550
+0.001 (0.09%)
Inactive · Last trade price
on Feb 11, 2025
Marinus Pharmaceuticals Employees
As of December 31, 2023, Marinus Pharmaceuticals had 166 total employees, including 165 full-time and 1 part-time employees. The number of employees increased by 13 or 8.50% compared to the previous year.
Employees
166
Change (1Y)
13
Growth (1Y)
8.50%
Revenue / Employee
$189,554
Profits / Employee
-$846,331
Market Cap
30.35M
Employees Chart
MRNS News
- 6 weeks ago - MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNS - Business Wire
- 7 weeks ago - Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc. - Business Wire
- 3 months ago - Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results - Business Wire
- 4 months ago - Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives - Business Wire
- 4 months ago - Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting - Business Wire
- 4 months ago - 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity - Benzinga
- 4 months ago - Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens - Business Wire
- 4 months ago - Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting - Business Wire